Advances in Plasma Cell Dyscrasias
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".
Deadline for manuscript submissions: closed (15 August 2024) | Viewed by 2426
Special Issue Editors
Interests: AL amyloidosis; multiple myeloma; Waldenström’s macroglobulinemia; thrombosis in plasma cell dyscrasias
Interests: multiple myeloma; Waldenström’s macroglobulinemia; AL amyloidosis; clinical trials
Interests: multiple myeloma; Waldenström’s macroglobulinemia; AL amyloidosis; liver cancer; meta-analysis; immunotherapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Plasma cell dyscrasias are a biologically and clinically heterogeneous group of diseases primarily characterized by the clonal expansion of plasma cells and monoclonal protein secretion. Significant research advances in the field during the past few years have led to improved outcomes for patients with multiple myeloma, AL amyloidosis and lymphoproliferative disorders such as Waldenström’s macroglobulinemia. The ever-increasing understanding of the molecular mechanisms involved in disease pathogenesis and interactions in the tumor microenvironment have led to improved diagnostics, prognostication and novel agent development. Risk characterization of smoldering multiple myeloma has changed, and treatment initiation has shifted to earlier stages of disease. Minimal residual disease assessment by NGF and NGS has become a surrogate endpoint in clinical trials, and is being increasingly incorporated into clinical practice as it reflects the depth of disease remission and correlates strongly with prognosis for patients with multiple myeloma and AL amyloidosis. In addition to immunomodulatory agents, proteasome inhibitors and anticd38 monoclonal antibodies, novel molecular targets and cellular immunotherapies such as chimeric antigen receptor T cells and/or bispecific antibodies have changed the treatment landscape. Immunotherapy will probably be the next revolution in treatment for plasma cell malignancies. Patients with plasma cell leukemia, POEMs and other rare entities have also benefited from the development of new agents. The goal of this Special Issue is to highlight important advances that have taken place in the diagnosis, management and treatment of plasma cell dyscrasias in recent years, and welcomes all papers that address aspects in these areas.
Dr. Despina Fotiou
Dr. Maria Gavriatopoulou
Dr. Ioannis Ntanasis-Stathopoulos
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- multiple myeloma
- smoldering multiple myeloma
- AL amyloidosis
- Waldenström’s macroglobulinemia
- adoptive T-cell therapies
- immunotherapy
- measurable residual disease
- POEMs
- plasma cell leukemia
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
